Cargando…

Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma

Inflammation is considered to be a prognostic factor for renal cell carcinoma (RCC). An inflammation-based prognostic score (modified Glasgow Prognostic Score; mGPS) is widely used for preoperative patients; however, little information is available regarding its prognostic value in patients with RCC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ohmura, Hirofumi, Uchino, Keita, Kajitani, Tatsuhiro, Sakamoto, Naotaka, Baba, Eishi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431320/ https://www.ncbi.nlm.nih.gov/pubmed/28515920 http://dx.doi.org/10.3892/mco.2017.1205

Ejemplares similares

A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine
por: Takayoshi, Kotoe, et al.
Publicado: (2015)

Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer
por: Kawagoe, Shiho, et al.
Publicado: (2019)

External validation of the modified Glasgow prognostic score for renal cancer
por: Tai, Caroline G., et al.
Publicado: (2014)

Biliary drainage improves the predictive value of modified Glasgow Prognostic Scores in inoperable pancreatic cancer
por: Iino, Chikara, et al.
Publicado: (2017)

A Meta-Analysis of Glasgow Prognostic Score and Modified Glasgow Prognostic Score as Biomarkers for Predicting Survival Outcome in Renal Cell Carcinoma
por: Tong, Tongyu, et al.
Publicado: (2020)

The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis
por: Zhang, Huan, et al.
Publicado: (2020)

The high-sensitivity modified Glasgow prognostic score is superior to the modified Glasgow prognostic score as a prognostic predictor for head and neck cancer
por: Hanai, Nobuhiro, et al.
Publicado: (2018)

Glasgow prognostic score is a better predictor of the long-term survival in patients with gastric cancer, compared to the modified Glasgow prognostic score or high-sensitivity modified Glasgow prognostic score
por: Hirahara, Noriyuki, et al.
Publicado: (2020)

Prognostic Value of the Modified Glasgow Prognostic Score in Patients Undergoing Radical Surgery for Hepatocellular Carcinoma
por: Ni, Xiao-Chun, et al.
Publicado: (2015)

Glasgow Prognostic Score and modified Glasgow Prognostic Score and survival in patients with hepatocellular carcinoma: a meta-analysis
por: Lu, Lingling, et al.
Publicado: (2021)

Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel
por: Ando, Keisuke, et al.
Publicado: (2021)

Prognostic value of preoperative high-sensitivity modified Glasgow prognostic score in advanced colon cancer: a retrospective observational study
por: Kasahara, Kenta, et al.
Publicado: (2022)

The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma
por: Tian, Rui, et al.
Publicado: (2016)

Modified Glasgow Prognostic Score is Better for Predicting Oncological Outcome in Patients with Soft Tissue Sarcoma, Compared to High-Sensitivity Modified Glasgow Prognostic Score
por: Nakamura, Tomoki, et al.
Publicado: (2022)

Prognostic value of pretreatment modified Glasgow Prognostic Score in small cell lung cancer: A meta-analysis
por: Xie, Yulian, et al.
Publicado: (2023)

Trousseau’s Syndrome with Advanced Neuroendocrine Carcinoma of Colon: A Case Report
por: Ohmura, Hirofumi, et al.
Publicado: (2023)

Modified Glasgow prognostic score as a prognostic factor for renal cell carcinomas: a systematic review and meta-analysis
por: Hu, Xu, et al.
Publicado: (2019)

A comprehensive analysis of Glasgow Prognostic Score (GPS)/the modified Glasgow Prognostic Score (mGPS) on immune checkpoint inhibitor efficacy among patients with advanced cancer
por: Zhang, Yongchao, et al.
Publicado: (2022)

Utility of the High-Sensitivity Modified Glasgow Prognostic Scores for Oropharyngeal Carcinoma
por: Iuchi, Hiroyuki, et al.
Publicado: (2021)

Prognostic value of preoperative modified Glasgow prognostic score in surgical non-small cell lung cancer: A meta-analysis
por: Yang, Chenli, et al.
Publicado: (2023)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma
por: Saal, Jonas, et al.
Publicado: (2023)

Validation of the conventional Glasgow Prognostic Score and development of the improved Glasgow Prognostic Score in patients with stage 0‐III colorectal cancer after curative resection
por: Ishikawa, Satoshi, et al.
Publicado: (2021)

Utility of the Modified and High-Sensitivity Modified Glasgow Prognostic Scores for Hypopharyngeal Squamous Cell Carcinoma
por: Iuchi, Hiroyuki, et al.
Publicado: (2021)

Prognostic Value of the Glasgow Prognostic Score on Overall Survival in patients with Advanced Non-Small Cell Lung Cancer
por: Pan, Mingmei, et al.
Publicado: (2021)

The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction
por: Jomrich, Gerd, et al.
Publicado: (2018)

Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Pancreatic Cancer: A Meta-Analysis
por: Fu, Wen, et al.
Publicado: (2020)

The prognostic value of pretreatment Glasgow Prognostic Score in patients with esophageal cancer: a meta-analysis
por: Wang, Yan, et al.
Publicado: (2019)

Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer
por: Stokke, Kristin, et al.
Publicado: (2022)

Prognostic Utility of the Modified Glasgow Prognostic Score in Urothelial Carcinoma: Outcomes from a Pooled Analysis
por: Tan, Daqing, et al.
Publicado: (2022)

Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis
por: Jin, Jing, et al.
Publicado: (2017)

The modified Glasgow prognostic score in Crohn’s disease—does it predict short-term outcome?
por: Argeny, Stanislaus, et al.
Publicado: (2018)

Glasgow prognostic score and combined positive score for locally advanced rectal cancer
por: Feng, Yanru, et al.
Publicado: (2022)

Prognostic value of the Glasgow prognostic score in colorectal cancer: a meta-analysis of 9,839 patients
por: Lu, Xin, et al.
Publicado: (2018)

Modified Glasgow prognostic score predicts the prognosis of patients with advanced esophageal squamous cell carcinoma: A propensity score‐matched analysis
por: Cui, Chanjuan, et al.
Publicado: (2022)

The Modified Glasgow Prognostic Score as a Predictor of Survival After Hepatectomy for Colorectal Liver Metastases
por: Nakagawa, Kazuya, et al.
Publicado: (2014)

The inflammation‐based modified Glasgow prognostic score is associated with survival in stable heart failure patients
por: Cho, Anna, et al.
Publicado: (2020)

Prediction of Treatment Response and Survival with Chemotherapy for Metastatic Penile Cancer by the Modified Glasgow Prognostic Score
por: Draeger, Desiree-Louise, et al.
Publicado: (2023)

Prognostic and clinical significance of modified glasgow prognostic score in pancreatic cancer: a meta-analysis of 4,629 patients
por: Wu, Dongdong, et al.
Publicado: (2021)

Prognostic Value of C-Reactive Protein, Glasgow Prognostic Score, and C-Reactive Protein-to-Albumin Ratio in Colorectal Cancer
por: Zhou, Jiahui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_upr4oqfdv5ls8l6bel32vrhlpq